CFO interim
Gain Therapeutics, Inc. names Gene Mack interim CFO
Gain Therapeutics, Inc. reported in a Form 8-K filed September 28, 2026 that Gene Mack was named interim interim Chief Financial Officer, effective October 1, 2026.
In the filing's words
On September 24, 2026, the Company’s board of directors appointed Gene Mack, the Company’s current President and Chief Executive Officer, to serve as the Company’s interim Chief Financial Officer, effective as of October 1, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Gain Therapeutics, Inc. (GANX) |
|---|---|
| Event | Interim |
| Incoming | Gene Mack |
| Outgoing | Gianluca Fuggetta |
| Title in the filing | interim Chief Financial Officer |
| Effective | October 1, 2026 |
| 8-K filed | September 28, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | President and Chief Executive Officer, Gain Therapeutics, Inc. |
| SEC CIK | 0001819411 |
Gain Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 28, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-29
Something wrong about Gene Mack? Send a correction with the primary source.